multiple myeloma

Dec 9, 2020

Sebia, Netherlands Universities to Develop Test for Disease Status in Patients With Multiple Myeloma

Feb 26, 2020

Adaptive Biotechnologies Q4 Revenues Rise 41 Percent

Feb 4, 2020

SkylineDx Partners With German Hospital to Assess Multiple Myeloma Test

Jan 7, 2020

Sebia to Develop Dx Test for Sanofi Multiple Myeloma Treatment

Dec 20, 2019

Telo Genomics, Mayo Clinic Collaborate on Multiple Myeloma Clinical Studies

Dec 9, 2019

Adaptive Biotechnologies, AbbVie Partner on MRD Testing in Multiple Myeloma Drug Trials

Aug 14, 2019

Adaptive Biotechnologies Plans New Product Launches, Expanded FDA Label for ClonoSeq
Premium

Jul 11, 2019

Diagnostics Firm Binding Site Developing MALDI Myeloma Test Based on Mayo Clinic Assay
Premium

Jan 18, 2019

Medicare Covers Adaptive Biotechnologies' ClonoSeq Assay

Oct 1, 2018

FDA Authorizes Adaptive Biotechnologies NGS Test for Minimal Residual Disease

May 2, 2018

U of Kansas Researchers, BioFluidica Develop Microfluidic-Based Diagnostic for Cancer
Premium

Feb 15, 2018

Dutch Researchers Develop Mass Spec Test for Multiple Myeloma
Premium

Jan 26, 2018

FDA Clears Test for Assessing Patients Treated with Multiple Myeloma Drug

Dec 13, 2017

Abingdon Health Raises £1.1M

Dec 12, 2017

Heroin Detection Assay, Kidney Injury System Cleared by FDA in November

Apr 18, 2017

SkylineDx Develops Tool to Predict Cancer Therapies Based on Genomic Data
Premium

Jan 30, 2017

Sebia, Janssen Biotech Ink Multiple Myeloma IVD Test Agreement

Oct 21, 2016

Mayo Clinic Developing MALDI-MS Assay for Monitoring Plasma Cell Disorders
Premium

Oct 21, 2016

SkylineDx Follows Multiple Myeloma MDx With Collaborative Effort to Develop Therapy Selection Assay
Premium